Humacyte rustles up $12 million and a new chief executive

MedCity News logo

Duke University spin-off Humacyte Inc. landed a $12 million investment and pharmaceutical industry veteran Carrie Cox for CEO.

The Durham, N.C.-based regenerative medicine company recently raised $12 million from a single investor through a debt offering, according to an amended filing with the Securities & Exchange Commission. Another amended filing shows the company raised $7 million in debt about a year ago.

Humacyte founder and former CEO Dr. Laura Niklason would say only that “we have taken in funds from our existing investors,” when asked by the Triangle Business Journal about the recent investments and their purposes.

Humacyte uses a proprietary technology to engineer human tissues that can be shaped into tubes, sheets and other forms to treat vascular diseases and repair the body. Niklason, a former Duke researcher, started the company in late 2004 to use human cells to make artificial blood vessels that could be transplanted into patients suffering from kidney failure and other ailments, the Triangle Business Journal said.

Cox, who had been executive vice president and president of Global Pharmaceuticals at Schering-Plough Corp., will assumer her new role on Sept. 20, according to Humacyte. She is expected to lead the young Research Triangle Park company from its development to its commercialization phase.

“We are clearly delighted to have an executive with the experience, leadership and sound business judgment of Carrie Cox to lead Humacyte at this important juncture in our company’s history,” Niklason said in prepared remarks. “Carrie is ideally qualified to oversee our ongoing product development efforts and lead us into commercialization of these much-needed treatment options for patients.”

Cox left Schering-Plough with a golden parachute estimated at between $36 million and $44 million when her company was acquired by Merck & Co. in November 2009, according to a pharmaceutical industry blog. That doesn’t include about $11 million in net gains from exercising Schering-Plough stock options in April and May of 2007 — before the release of disappointing study results on the company’s Vytorin cholesterol-lowering drug.

Those stock option sales are part of an ongoing class-action shareholder lawsuit that alleges securities misdeeds by Schering-Plough executives. Some posts at a CafePharma message board on the topic were submitted as evidence in the case. In June, a federal district court judge upheld an August 2009 decision to deny defendants’ request to dismiss the case.

In December, Cox signed on as a director of drug distributor Cardinal Health, Ohio’s largest corporation. Fortune Magazine has named Cox to its list of the 50 Most Powerful Women in Business six times, according to Cardinal and Humacyte.

“I am proud to join Humacyte and become part of creating the future of regenerative medicine,” Cox said in the release. “The breakthrough science being conducted at Humacyte may one day bring major benefits to patients, while also improving health outcomes and reducing costs.”

RSS From Medical Design & Outsourcing

  • Athermal laser machining cuts bioabsorbable polymers and more
    A the recent MD&M East trade show in New York, Norman Noble, discussed the capability of athermal laser manufacturer. The company has developed the Noble S.T.E.A.L.T.H. (System To Enable Ablation Laser Technology Haz-free). The athermal laser machining process was developed to create precise features in any material, including bioabsorbable polymers, shape memory metals and other […]
  • Exciting possibilities for metallic glass in the medical device world
    Researchers are exploring the potential of metallic glass as a versatile, pliable material that is stronger than steel, with a bevy of possible medical device applications. Yale University engineers have discovered a unique method for designing metallic glass nanostructures across a wide range of chemicals, a technique that could have applications for everything from watch […]
  • Strong Precision Technologies’ medical divisions to unify under MedTorque brand
    Strong Precision Technologies announced on July 2, 2015, that its two medical divisions will now go to market under a single brand, MedTorque. The move reflects the increasing integration of the division formerly known as Inland Midwest with MedTorque, its sister division in Kenosha, WI. “We will continue providing our customers with the personalized level of service […]
  • Olympus offers next-day product replacement guarantee for medical devices
    Olympus, a medical and surgical procedures solutions company, announced that it is guaranteeing next-day replacements for surgical equipment at no additional charge. Olympus is the first surgical product manufacturer to offer this type of guarantee. The service became available to customers with an Olympus Full Service Agreement earlier this year. “Canceled procedures can be costly for healthcare facilities […]
  • More accurate prediction on prognosis in multiple myeloma from SkylineDx
    SkylineDx, a biotechnology company specializing in the development and commercialization of genetic tests, is launching its MMprofiler assay. This test enables clinicians to more accurately predict the prognosis of patients with multiple myeloma (bone marrow cancer) than traditional methods. The MMprofiler measures the activity of 92 genes which are directly or indirectly related to the […]
  • Flint Mobile swaps card reader for camera, accept mobile payments anywhere
    Flint Mobile, the swipe-free mobile payments app, has significantly expanded its payment management and loyalty capabilities for small, service-centric businesses, like the ones run by on-the-go medical equipment professionals. The toggle-free mobile technology makes the process quite simple for both parties, as all transactions are conducted through the mobile device’s camera without the need of any external […]
  • Should scientists be allowed to genetically alter human embryos?
    Scientists have at their disposal, a way to explore the possible prevention of genetic diseases before birth. But should they? Currently, the most promising path forward involves editing the genes of human embryos, a procedure threaded with controversy. An article in “Chemical & Engineering News” (C&EN), the weekly newsmagazine of the American Chemical Society (ACS), parses […]
  • Tackling chronic sinusitis by addressing underlying factors
    The stuffy noses and sinus pressure of head colds are uncomfortable, but for most people, they go away within days. For those with chronic sinusitis, however, those symptoms and others drag on for weeks. Now scientists are onto a potential new therapy that could address one of the underlying factors associated with the condition. They […]
  • Implantable “artificial pancreas” could help diabetes patients control their blood sugar
    Living with Type 1 diabetes requires constant monitoring of blood sugar levels and injecting insulin daily. Now scientists are reporting in the American Chemical Society (ACS) journal, “Industrial & Engineering Chemistry Research,” the development of an implantable “artificial pancreas” that continuously measures a person’s blood sugar or glucose level and can automatically release insulin as […]
  • Drug Deactivation program roll out to all facilities for safe disposal of unused prescription medications
    Verde Technologies announced that New Brighton-based Meridian Behavioral Health, the largest for-profit substance abuse and addiction treatment group in Minnesota, has become its most recent partner in the deactivation and safe disposal of prescription medications including methadone. Meridian is the first behavioral health group to roll out the Deterra Drug Deactivation System to all 17 […]
  • Lophius Biosciences introduces T-activated ImmunoScan Cocktail
    Lophius Biosciences announced the commercial launch of T-Track ImmunoScan and T-activated ImmunoScan Cocktail. Based on a proprietary and very specific cocktail of stimulants in combination with the Company’s T-activation technology, T-Track ImmunoScan and T-activated ImmunoScan Cocktail specifically target different cell types involved in both the adaptive and innate immune system. T-Track ImmunoScan and the T-activated […]

Leave a Reply